Oddbjorn Straume
Overview
Explore the profile of Oddbjorn Straume including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lereim R, Dunn C, Aamdal E, Chauhan S, Straume O, Guren T, et al.
Oncoimmunology
. 2024 Dec;
14(1):2440967.
PMID: 39703053
The immune checkpoint inhibitor ipilimumab provides long term survival in some metastatic melanoma patients, but the majority has no benefit, and may experience serious side effects. Here, we investigated the...
2.
Schuster C, Akslen L, Straume O
Cancer Med
. 2023 Aug;
12(17):17891-17900.
PMID: 37551424
Background: Vascular endothelial growth factor (VEGF) was initially known as vascular permeability factor and identified as a driver of tumour angiogenesis. Recently, its role in supporting an immunosuppressive tumour microenvironment...
3.
Sommerfelt H, Sandvik L, Bachmann I, Brekke R, Svendsen H, Guttormsen A, et al.
Acta Oncol
. 2022 Sep;
61(10):1295-1299.
PMID: 36073292
No abstract available.
4.
Aamdal E, Jacobsen K, Straume O, Kersten C, Herlofsen O, Karlsen J, et al.
Int J Cancer
. 2021 Aug;
150(1):100-111.
PMID: 34449877
Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and...
5.
Kruger K, Silwal-Pandit L, Wik E, Straume O, Stefansson I, Borgen E, et al.
Sci Rep
. 2021 Feb;
11(1):3388.
PMID: 33564016
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value...
6.
Engelsen A, Wnuk-Lipinska K, Bougnaud S, Pelissier Vatter F, Tiron C, Villadsen R, et al.
iScience
. 2020 Oct;
23(11):101649.
PMID: 33103086
The receptor tyrosine kinase AXL is associated with epithelial plasticity in several solid tumors including breast cancer and AXL-targeting agents are currently in clinical trials. We hypothesized that AXL is...
7.
Seo M, Straume O, Akslen L, Cairns J
Pharmacoecon Open
. 2020 Jan;
4(3):529-539.
PMID: 31989465
Background: Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies...
8.
Forthun R, Hovland R, Schuster C, Puntervoll H, Brodal H, Namlos H, et al.
Sci Rep
. 2019 Nov;
9(1):17471.
PMID: 31767937
Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA...
9.
Dillekas H, Rogers M, Straume O
Cancer Med
. 2019 Aug;
8(12):5574-5576.
PMID: 31397113
Numerous publications have stated that metastases are responsible for 90% of cancer deaths, but data underlying this assertion has been lacking. Our objective was to determine what proportions of cancer...
10.
Demicheli R, Dillekas H, Straume O, Biganzoli E
Breast Cancer Res
. 2019 May;
21(1):57.
PMID: 31046808
Background: The aim of the research was to separate the distant metastasis (DM) enhancing effect due to breast tumour removal from that due to surgical manoeuvre by itself. Methods: DM...